Alexander KarpAlexander Karp earned $1B in 2024

In 2009, Dr. Geoffrey Allan earned $1.61M in total compensation at Insmed, including $209.64K salary and $699.58K in stock. Led Insmed as CEO for 3 years.

Compensation History

Annual executive compensation data for Dr. Geoffrey Allan, including salary, bonuses, and stock awards.

Year

2009

Total Compensation

$1.61M

Salary

$209.64K

Bonus

$0.00

Other

$699.58K

Salary

$209.64K

Board Justification

The company's compensation philosophy aims to attract, retain, and motivate highly qualified executives while aligning compensation with shareholder interests and performance metrics.

Bonus

$0.00

Board Justification

No bonus was awarded for fiscal 2009 as he was only employed for a partial year before resigning due to health reasons.

Other Compensation

$699.58K

Board Justification

Includes a lump sum severance payment of $675,000 and other benefits related to the personal use of a vehicle provided by the company.

Restricted Stock

$699.58K247.58K restricted stock

Board Justification

The 2008 restricted stock and restricted stock unit grants to Dr. Allan vested on March 31, 2009 as a result of the Merck transaction prior to his resignation.

Performance Metrics

The performance metrics for 2009 included the successful conclusion of the sale of Follow on Biologics assets to Merck, completion of clinical trials, and strategic business reviews.

I

Dr. Geoffrey Allan

Ex-CEO of Insmed

Education

N/A

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

June 19, 1958 - 67 years ago

CEO of Insmed for

3 years 10 months (Aug 2005 - Jun 2009)

Previous Experience

N/A

Holdings

Track Dr. Geoffrey Allan's stock holdings and portfolio value over time.

Insider Trading

Dr. Geoffrey Allan's recent stock transactions, purchases, and sales filed with the SEC.

No insider trades found for this CEO.

Rivals

Compare Dr. Geoffrey Allan with competitor CEOs and industry peers.